Last reviewed · How we verify
NCT05825339: AF-INOCA
Absolute Flow for Ischemia With No Obstructive Coronary Arteries
trial testing Coronary Flow Reserve in Coronary Microvascular Dysfunction in 121 participants. Status unknown.
30 April 2024
Quick facts
| Lead sponsor | Spanish Society of Cardiology |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 121 |
| Start date | 1 May 2021 |
| Primary completion | 30 April 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 6 locations across Spain |
Drugs / interventions tested
- Coronary Flow Reserve
Conditions studied
- Coronary Microvascular Dysfunction — all drugs for Coronary Microvascular Dysfunction →
- Coronary Microvascular Disease — all drugs for Coronary Microvascular Disease →
- Angina, Stable — all drugs for Angina, Stable →
Sponsor
Spanish Society of Cardiology
Who can join
18 and older, any sex, with Coronary Microvascular Dysfunction or Coronary Microvascular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective is to prospectively validate the capacity of continuous thermodilution coronary flow reserve (CFRflow) as a predictor of the presence of angina measured by SAQ7 in patients with INOCA at 3 months. Secondary objectives include identifying hemodynamic factors related to the persistence of angina at 3 and 12 months, identifying clinical factors associated with the persistence of angina, establishing the prevalence of patients with coronary microvascular dysfunction within the cohort of INOCA patients, identifying predictors of major cardiovascular events at 12 months, validating the pathological value of MMR and establishing the pathological value of AF measured in ml/min. The study also aims to evaluate the concordance between measures of the coronary microvascular function obtained by continuous thermodilution and bolus thermodilution, as well as their concordance with clinical characteristics.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05825339
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Microvascular Dysfunction
Currently open trials in the same condition.
- NCT06795035 — Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution · recruiting
- NCT06606821 — The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease · Phase 4 · recruiting
- NCT06597851 — Insulin Resistance and Coronary Microvascular Dysfunction in Patients with Myocardial Ischemia and Non-obstructive Coron · NA · recruiting
- NCT06393478 — Southeastern Europe Microcirculation Registry · recruiting
- NCT06376630 — Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI · NA · recruiting
Other Spanish Society of Cardiology trials
Trials by the same sponsor.
- NCT06755801 — Nebivolol ANOCA Treatment Randomized Trial · Phase 3 · not yet recruiting
- NCT05619601 — Gender Differences in Prevention Strategies and Therapeutic Adherence After Acute Myocardial Infarction · active not recruiting
- NCT04674475 — OPTImized Coronary Interventions eXplaIn the bEst cliNical outcomEs · unknown
- NCT04850417 — Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection · Phase 4 · not yet recruiting
- NCT04696185 — Dapagliflozin After Transcatheter Aortic Valve Implantation · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05825339 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Spanish Society of Cardiology
- Last refreshed: 24 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05825339.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing